296 related articles for article (PubMed ID: 32515579)
1. Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.
Xu Z; Tsai HI; Xiao Y; Wu Y; Su D; Yang M; Zha H; Yan F; Liu X; Cheng F; Chen H
ACS Nano; 2020 Jul; 14(7):7959-7969. PubMed ID: 32515579
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation.
Yang M; Xu Z; Yan H; Tsai HI; Su D; Yan F; Lu Q; Feng J; Zeng W; Xi L; Zha H; Ling Y; He C; Wu Y; Xu X; Zheng G; Liu G; Chen H; Cheng F
Biomater Sci; 2021 Feb; 9(4):1246-1255. PubMed ID: 33367372
[TBL] [Abstract][Full Text] [Related]
3. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
5. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
[TBL] [Abstract][Full Text] [Related]
6. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
7. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies.
Watari K; Konnai S; Okagawa T; Maekawa N; Sajiki Y; Kato Y; Suzuki Y; Murata S; Ohashi K
J Vet Med Sci; 2022 Jan; 84(1):6-15. PubMed ID: 34789592
[TBL] [Abstract][Full Text] [Related]
9. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
10. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.
Li B; Yang T; Liu J; Yu X; Li X; Qin F; Zheng J; Liang J; Zeng Y; Zhou Z; Liu L; Zhang B; Yao W; Feng Z; Zeng G; Zhou Q; Chen L
Acta Biomater; 2023 Apr; 161():184-200. PubMed ID: 36893957
[TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.
Kennedy A; Robinson MA; Hinze C; Waters E; Williams C; Halliday N; Dovedi S; Sansom DM
EMBO J; 2023 Mar; 42(5):e111556. PubMed ID: 36727298
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
15. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
[TBL] [Abstract][Full Text] [Related]
16. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology.
Hafalla JC; Claser C; Couper KN; Grau GE; Renia L; de Souza JB; Riley EM
PLoS Pathog; 2012 Feb; 8(2):e1002504. PubMed ID: 22319445
[TBL] [Abstract][Full Text] [Related]
17. Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.
Samiei A; Gjertson DW; Memarzadeh S; Konecny GE; Moatamed NA
Diagn Pathol; 2022 Sep; 17(1):70. PubMed ID: 36104728
[TBL] [Abstract][Full Text] [Related]
18. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.
Xu X; Liu L; Wang H; Li W; Zou Y; Zeng Y; Yang Q; Bai D; Dai D
ACS Biomater Sci Eng; 2022 Nov; 8(11):4819-4826. PubMed ID: 36206367
[TBL] [Abstract][Full Text] [Related]
19. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
[TBL] [Abstract][Full Text] [Related]
20. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]